ReviewNeurochemical research2022
Lipid-Based Nanocarriers via Nose-to-Brain Pathway for Central Nervous System Disorders.
Review in Neurochemical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Recent Advances in Intranasal Administration for Brain-Targeting Delivery: A Comprehensive Review of Lipid-Based Nanoparticles and Stimuli-Responsive Gel Formulations.International journal of nanomedicine · 2024Pooled it
- Disease mechanisms and translational barriers guide nanocarrier design for nose to brain delivery in Alzheimer's disease.Discover nano · 2026Review
- On The Retrograde Transport of RNA-Loaded Lipid Nanoparticles Designed for Brain Delivery.ACS nanoscience Au · 2025Article
- Thermosensitive, mucoadhesive brivaracetam nasal gel: a promising strategy for targeted relief of epilepsy.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Recent Advances in Donepezil Delivery Systems via the Nose-to-Brain Pathway.Pharmaceutics · 2025Review
- Nanoformulation innovations: Revolutionizing precision in migraine therapy.Iranian journal of basic medical sciences · 2025Review
- A comprehensive insight of innovations and recent advancements in nanocarriers for nose-to-brain drug targeting.Designed monomers and polymers · 2025Review
- Nanomedicine in Neuroprotection, Neuroregeneration, and Blood-Brain Barrier Modulation: A Narrative Review.Medicina (Kaunas, Lithuania) · 2024Review
- An Overview on the Physiopathology of the Blood-Brain Barrier and the Lipid-Based Nanocarriers for Central Nervous System Delivery.Pharmaceutics · 2024Review
- Cubosomes as versatile lipid nanocarriers for neurological disorder therapeutics: a comprehensive review.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Lipid and Transcriptional Regulation in a Parkinson's Disease Mouse Model by Intranasal Vesicular and Hexosomal Plasmalogen-Based Nanomedicines.Advanced healthcare materials · 2024Article
- Nasal Delivery to the Brain: Harnessing Nanoparticles for Effective Drug Transport.Pharmaceutics · 2024Review
- Chitosan-coated nanostructured lipid carriers for effective brain delivery of Tanshinone IIA in Parkinson's disease: interplay between nuclear factor-kappa β and cathepsin B.Drug delivery and translational research · 2024Article
- How Precise are Nanomedicines in Overcoming the Blood-Brain Barrier? A Comprehensive Review of the Literature.International journal of nanomedicine · 2024Review
- Solid Lipid Nanoparticles Containing Dopamine and Grape Seed Extract: Freeze-Drying with Cryoprotection as a Formulation Strategy to Achieve Nasal Powders.Molecules (Basel, Switzerland) · 2023Article
- An updated review on oral protein-based antigen vaccines efficiency and delivery approaches: a special attention to infectious diseases.Archives of microbiology · 2023Review
- Recent Advancements in Nanomaterials: A Promising Way to Manage Neurodegenerative Disorders.Molecular diagnosis & therapy · 2023Review
- Recent Advances in the Development of Liquid Crystalline Nanoparticles as Drug Delivery Systems.Pharmaceutics · 2023Review
- Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications.Pharmaceutics · 2023Review
- Lipid-based nanoparticles via nose-to-brain delivery: a mini review.Frontiers in cell and developmental biology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative disorders are distinguished by the gradual deterioration of the nervous system's structure and function due to oxidative stress, mitochondrial dysfunction, protein misfolding, excitotoxicity, and neuroinflammation. Among these NDs, Alzheimer's disease, Huntington's disease, Parkinson's disease, and amyotrophic lateral sclerosis characterized an increasing dysfunction and loss of neuronal structure leading to neuronal cell death. Although there is currently no drug to totally reverse the effects of NDs, such novel formulations and administration routes are developed for better management and nose-to-brain delivery is one of delivery for treating NDs. This review aimed to highlight advances in research on various lipid based nanocarriers such as liposomes, solid lipid nanoparticles, nanostructured lipid carriers, microemulsion, nanoemulsion, and cubosomes which are reported to treat and alleviate the symptoms of NDs via nose-to-brain route. The challenges during clinical translation of lipid nanocarriers from bench to bed side is also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.